ReviewThe European respiratory journal2021
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation.
Review in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Application of type 2 inflammation-related biomarkers in risk prediction models for acute exacerbations in adult asthma: a systematic review.Frontiers in medicine · 2026Pooled it
- Tear Levels of Inflammatory Cytokines in Keratoconus: A Meta-Analysis of Case-Control and Cross-Sectional Studies.BioMed research international · 2021Pooled it
- Resting state functional connectivity changes following mindfulness-based stress reduction predict improvements in disease control for patients with asthma.Brain, behavior, and immunity · 2024Trial
- Bacterial lysate add-on therapy to reduce exacerbations in severe asthma: A double-blind placebo-controlled trial.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Trial
- Role and mechanism of quercetin via the TLR4/MyD88/IRAK4 signaling pathway in the treatment of allergic rhinitis.Experimental and therapeutic medicine · 2026Article
- Long-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain.Journal of clinical medicine · 2026Article
- Unsupervised Machine-Learning-Based Endotype Discovery Using Iterative Resampling in Dupilumab-Treated Patients.International journal of molecular sciences · 2026Article
- Review
- The role of nasal microbiota and type 2 innate lymphoid cells in the pathogenesis of allergic rhinitis.Biochemistry and biophysics reports · 2026Article
- S100P mediates IL-13/ATF4-driven epithelial barrier dysfunction in eosinophilic asthma: a potential biomarker and therapeutic target.Journal of translational medicine · 2026Article
- Systemic-airway eosinophil discordance and sputum mediator profiling in severe asthma treated with biologics: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Predicting clinical remission in biologic-treated severe asthma: development of a practical scoring system from a Japanese multicentre study.BMJ open respiratory research · 2026Article
- Misconceptions of Traits to Predict Response to Inhaled Corticosteroid and Bronchodilator Therapies in Asthma: A Narrative Review.Pulmonary therapy · 2026Review
- Beyond symptoms: uncovering type 2 inflammation and small airway dysfunction in Treatment-Naïve asthma.BMC pulmonary medicine · 2026Article
- Severe Asthma Exacerbations: From Risk Factors to Precision Management Strategies.Journal of clinical medicine · 2026Review
- Editorial: Impact of viral infections on childhood asthma: susceptibility and pathomechanisms.Frontiers in allergy · 2026Article
- Flavonoids as potential anti-asthmatic agents.Frontiers in immunology · 2026Review
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study.The journal of allergy and clinical immunology. Global · 2026Article
- The Major Role of Type 2 Inflammation in Asthma: From the Perspective of Immunological Mechanism.BioMed research international · 2026Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
Abstract
Asthma is a complex respiratory disease that varies in severity and response to treatment. Several asthma phenotypes with unique clinical and inflammatory characteristics have been identified. Endotypes, based on distinct molecular profiles, help to further elucidate the heterogeneity within asthma. Type 2 inflammation, involving both the innate (type 2 innate lymphoid cell) and adaptive (T-helper type 2 cells) immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.